1. Home
  2. KALV vs DCBO Comparison

KALV vs DCBO Comparison

Compare KALV & DCBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$15.48

Market Cap

757.7M

Sector

Health Care

ML Signal

HOLD

Logo Docebo Inc.

DCBO

Docebo Inc.

HOLD

Current Price

$19.81

Market Cap

489.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALV
DCBO
Founded
N/A
2016
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
757.7M
489.9M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
KALV
DCBO
Price
$15.48
$19.81
Analyst Decision
Strong Buy
Buy
Analyst Count
5
9
Target Price
$30.00
$32.00
AVG Volume (30 Days)
721.4K
251.9K
Earning Date
03-25-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,000,000.00
N/A
Revenue This Year
N/A
$12.54
Revenue Next Year
N/A
$11.82
P/E Ratio
N/A
$22.04
Revenue Growth
495.66
N/A
52 Week Low
$9.83
$16.07
52 Week High
$19.00
$33.69

Technical Indicators

Market Signals
Indicator
KALV
DCBO
Relative Strength Index (RSI) 45.58 53.88
Support Level $14.59 $18.11
Resistance Level $16.49 $20.15
Average True Range (ATR) 0.98 1.02
MACD -0.06 0.22
Stochastic Oscillator 13.35 48.88

Price Performance

Historical Comparison
KALV
DCBO

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About DCBO Docebo Inc.

Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.

Share on Social Networks: